Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses

By sjmartinez • March 21, 2024

Yuen MF, Fung S, Ma X, Nguyen TT, Hassanein T, Hann HW, Elkhashab M, Nahass RG, Park JS, Jacobson IM, Ayoub WS, Han SH, Gane EJ, Zomorodi K, Yan R, Ma J, Knox SJ, Stamm LM, Bonacini M, Weilert F, Ramji A, Bennett M, Ravendhran N, Chan S, Dieterich DT, Kwo PY, Schiff ER, Bae HS, Lalezari J, Agarwal K, Sulkowski MS. Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses. JHEP Rep. 2024 Jan 18;6(4):100999. doi: 10.1016/j.jhepr.2023.100999. PMID: 38510983; PMCID: PMC10951643.

Tags: Antiviral, Cedars Sinai DoM, Core inhibitor, Digestive Diseases, Hepatitis, hepatitis B virus, Nucleos(t)ide reverse transcriptase inhibitor, Off-treatment, Open-label, Publications, Viral relapse

Related Posts

Adverse Pregnancy Outcomes and N-Terminal Pro-Brain Natriuretic Peptide Levels 2 to 7 Years After Delivery: The nuMoM2b Heart Health Study

Freaney PM, Huang X, Petito LC, Grobman WA, Catov J, Hauspurg A, Bairey Merz CN, Bello N, Kim JK, Lane A, Haas DM, Levine LD,[...]

Effectiveness of mailed versus in-person PAP initiation in VA’s TeleSleep program

Gomez A, Sarmiento KF, Smith C, Mitchell M, Lee D, Totten A, Sanders E, Ryden AM, Seo J, Bhattacharyya S, Harris B, Mempin R, Moghtaderi[...]

Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial

Bandos H, Kim S, Henry NL, Hays RD, Calsavara VF, Luu M, Gresham G, Lu KY, Irvin WJ, Suga JM, Siddique S, Cecchini RS, Rogatko[...]